Literature DB >> 18537485

Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?

Todd M Brown1, Dhananjay Vaidya, William J Rogers, David D Waters, Barbara V Howard, Jean-Claude Tardif, Vera Bittner.   

Abstract

BACKGROUND: The definition and prognostic utility of the metabolic syndrome remain controversial. Analyses in predominantly healthy populations suggest that the International Diabetes Federation (IDF) definition identifies more men with metabolic syndrome than the Adult Treatment Panel III (ATP III) criteria, with little difference among women. Whether the IDF definition identifies a greater prevalence of the metabolic syndrome than the ATP III definition in women with coronary artery disease (CAD) is unknown.
METHODS: We compared the prevalence and prognostic utility of both definitions of the metabolic syndrome in postmenopausal women with angiographic CAD enrolled in the Women's Angiographic Vitamin and Estrogen Trial (WAVE). We excluded 51 of 423 women enrolled (12%) who had missing data for components of the metabolic syndrome.
RESULTS: Mean age was 65.3 +/- 8.4 years, 70% were white, mean body mass index (BMI) was 30.5 +/- 6.0 kg/m(2), mean waist circumference was 96.2 +/- 12.9 cm, 89% had hypertension by history or elevated blood pressure, 58% had diabetes or hyperglycemia, 54% had low high-density lipoprotein cholesterol (HDL-C), and 44% had hypertriglyceridemia. Metabolic syndrome prevalence was 70% and 74% by ATP III and IDF criteria, respectively; 68% met criteria for both definitions. Classification between the two criteria was not affected by ethnicity or age. Incident cardiovascular events were similar in both metabolic syndrome classifications.
CONCLUSIONS: Among postmenopausal women with angiographic CAD, the metabolic syndrome is very prevalent. The IDF modification of the ATP III definition only identifies a small additional number of women as having metabolic syndrome, independent of ethnicity or age, and provides little additional prognostic information.

Entities:  

Mesh:

Year:  2008        PMID: 18537485      PMCID: PMC2942788          DOI: 10.1089/jwh.2007.0536

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  23 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

3.  Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition.

Authors:  Robert J Adams; Sarah Appleton; David H Wilson; Anne W Taylor; Eleonora Dal Grande; Catherine Chittleborough; Tiffany Gill; Richard Ruffin
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

4.  Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions.

Authors:  Fernando Guerrero-Romero; Martha Rodríguez-Morán
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

5.  Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.

Authors:  David D Waters; Edwin L Alderman; Judith Hsia; Barbara V Howard; Frederick R Cobb; William J Rogers; Pamela Ouyang; Paul Thompson; Jean Claude Tardif; Lyall Higginson; Vera Bittner; Michael Steffes; David J Gordon; Michael Proschan; Naji Younes; Joel I Verter
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

7.  Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial.

Authors:  Judith Hsia; Vera Bittner; Mark Tripputi; Barbara V Howard
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

8.  Metabolic syndrome and mortality in stable coronary heart disease: relation to gender.

Authors:  Charlotte Kragelund; Lars Køber; Jens Faber; Rolf Steffensen; Per Hildebrandt
Journal:  Int J Cardiol       Date:  2007-06-12       Impact factor: 4.164

9.  Women's angiographic vitamin and estrogen trial: design and methods.

Authors:  Judith Hsia; Edwin L Alderman; Joel I Verter; William J Rogers; Paul Thompson; Barbara V Howard; Frederick R Cobb; Pamela Ouyang; Jean Claude Tardif; Lyall Higginson; Vera Bittner; Ivan Barofsky; Michael Steffes; David J Gordon; Michael Proschan; Naji Younes; David Waters
Journal:  Control Clin Trials       Date:  2002-12

10.  Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women.

Authors:  Q Qiao
Journal:  Diabetologia       Date:  2006-10-05       Impact factor: 10.122

View more
  9 in total

1.  The relationships between FAM5C SNP (rs10920501) variability and metabolic syndrome and inflammation in women with coronary heart disease.

Authors:  Jennifer L Cline; Theresa M Beckie
Journal:  Biol Res Nurs       Date:  2011-10-18       Impact factor: 2.522

2.  Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Todd M Brown; Jenifer H Voeks; Vera Bittner; Monika M Safford
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

3.  Prevalence of the metabolic syndrome in patients with carotid disease according to NHLBI/AHA and IDF criteria: a cross-sectional study.

Authors:  Milos Z Maksimovic; Hristina D Vlajinac; Djordje J Radak; Jelena M Marinkovic; Jagoda B Jorga
Journal:  BMC Cardiovasc Disord       Date:  2012-01-31       Impact factor: 2.298

4.  Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions?

Authors:  Hossein Khosravi-Boroujeni; Faruk Ahmed; Masoumeh Sadeghi; Hamidreza Roohafza; Mohammad Talaei; Minoo Dianatkhah; Ali Pourmogaddas; Nizal Sarrafzadegan
Journal:  BMC Public Health       Date:  2015-12-29       Impact factor: 3.295

5.  Prevalence of metabolic syndrome in elderly and agreement among four diagnostic criteria.

Authors:  Maria Auxiliadora Nogueira Saad; Gilberto Perez Cardoso; Wolney de Andrade Martins; Luis Guillermo Coca Velarde; Rubens Antunes da Cruz Filho
Journal:  Arq Bras Cardiol       Date:  2014-02-10       Impact factor: 2.000

6.  The type of fat ingested at breakfast influences the plasma lipid profile of postmenopausal women.

Authors:  J M Morillas-Ruiz; J M Delgado-Alarcon; J M Rubio-Perez; M D Albaladejo Oton
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

7.  Metabolic syndrome in premenopausal and postmenopausal women with type 2 diabetes: loss of protective effects of premenopausal status.

Authors:  Manouchehr Nakhjavani; Mehrnaz Imani; Mehrdad Larry; Arash Aghajani-Nargesi; Afsaneh Morteza; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2014-11-23

8.  The IDF Definition Is Better Suited for Screening Metabolic Syndrome and Estimating Risks of Diabetes in Asian American Adults: Evidence from NHANES 2011-2016.

Authors:  Lin Zhu; Cody Spence; Jenny Wei Yang; Grace X Ma
Journal:  J Clin Med       Date:  2020-11-28       Impact factor: 4.241

Review 9.  Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome.

Authors:  Helen H Wang; Dong Ki Lee; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.